Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
195 GBX | +5.41% | +1.30% | -36.07% |
May. 22 | Transcript : Faron Pharmaceuticals Oy - Special Call | |
May. 20 | Faron Pharmaceuticals’ Blood Cancer Combo Shows Efficacy in Mid-stage Study | MT |
Sales 2024 * | 14.4M 15.7M | Sales 2025 * | 39.09M 42.62M | Capitalization | 165M 180M |
---|---|---|---|---|---|
Net income 2024 * | -6M -6.54M | Net income 2025 * | -4M -4.36M | EV / Sales 2024 * | 13.6 x |
Net Debt 2024 * | 30.6M 33.36M | Net cash position 2025 * | 42.27M 46.08M | EV / Sales 2025 * | 3.14 x |
P/E ratio 2024 * |
-7.47
x | P/E ratio 2025 * |
-14.8
x | Employees | 34 |
Yield 2024 * |
0.65% | Yield 2025 * |
-
| Free-Float | 60.71% |
Latest transcript on Faron Pharmaceuticals Oy
1 day | +5.41% | ||
1 week | +1.30% | ||
Current month | +5.41% | ||
1 month | +30.00% | ||
3 months | +27.87% | ||
6 months | -28.83% | ||
Current year | -36.07% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 02-12-31 | |
Founder | 46 | 02-12-31 | |
Founder | 70 | 02-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 70 | 02-12-31 | |
Chairman | 60 | 23-03-23 | |
Founder | 46 | 02-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-03 | 195 | +5.41% | 25,363 |
24-05-31 | 185 | +4.23% | 25,070 |
24-05-30 | 177.5 | 0.00% | 5,038 |
24-05-29 | 177.5 | -1.39% | 6,947 |
Delayed Quote London S.E., June 03, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.07% | 169M | |
+15.55% | 118B | |
+12.66% | 106B | |
-2.53% | 24.28B | |
+1.14% | 21.96B | |
-9.35% | 18.16B | |
-42.28% | 16.37B | |
-18.92% | 15.56B | |
+6.19% | 13.63B | |
+28.83% | 12.27B |
- Stock Market
- Equities
- FARN Stock